Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

OS30 data at 3rd GBM Drug Development Summit. Boston, 1/20/2022, 8:40A EST
A Deep Dive into DNA Damage Repair for GBM
Jeffrey Skolnik
VP Clinical Development Inovio

Inovio’s DNA Medicine for the Treatment of Glioblastoma:
• Using novel DNA-encoded medicines to treat human cancers such as GBM
• Generating robust, specific anti-tumor T cells against GBM antigens
• Combining DNA medicine with immune checkpoint inhibitors to build clinical responses

https://s23.q4cdn.com/479936946/files/doc_presentations/INOVIO-Investor-Deck-Presentation_Nov2021.pdf

GBM 5401 Overall Survival at 24 Months
MGMT Unmethylated (Cohort A)
MGMT Methylated (Cohort B)
Combined
n Alive/N Total
7/32
11/20*
18/52

OS24% (95% CI)
21.9 (9.3 - 40)
55 (31.5 – 76.9)
34.6 (23.1 – 49.1)

Of the estimated 17,000 primary brain tumors diagnosed in the US each year, approximately 60% are gliomas.1,2 Glioblastoma (GB), or grade IV astrocytoma, is the most aggressive of primary tumors of the brain for which no cure is available.1,3 Management remains palliative and includes surgery, radiotherapy, and chemotherapy. With optimal treatment, patients with GBs have a median survival of less than one year.1 About 2% of patients survive three years.4 Previously reported long-term survivors (LTSs) of GB may have been patients who actually harbored other low-grade gliomas.5 The overall prognosis for GB has changed little since the 1980s, despite major improvements in neuroimaging, neurosurgery, radiotherapy, and chemotherapy techniques.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037140/#!po=46.0000